Navigation Links
U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'RESUS' Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
Date:3/23/2009

CAMBRIDGE, Mass., March 23 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the U.S. Naval Medical Research Center (NMRC) has submitted to the Food and Drug Administration (FDA) a revised investigational new drug (IND) application to conduct a clinical trial of the company's oxygen therapeutic Hemopure(R) [hemoglobin glutamer - 250 (bovine)] for the pre-hospital treatment of trauma patients. The study is entitled "Restore Effective Survival in Shock" (RESUS). The RESUS trial was first proposed and submitted to the FDA in 2005. The proposed trial was placed on clinical hold at that time. It has been resubmitted repeatedly in response to FDA comments and to address comments made by the FDA Blood Products Advisory Committee at an open meeting held in December 2006. Each subsequent submission was placed on clinical hold.

Under a research agreement with Biopure, the NMRC assumed primary responsibility, subject to funding, for designing, seeking FDA acceptance of and directing a trial for Hemopure's prehospital used in trauma patients with hemorrhagic shock. The NMRC has developed protocols for trials in civilian casualties in the United States and abroad (RESUS) as well as a trial proposed to be conducted in the field, called Operation RESUS (OP RESUS). To date, Congress has appropriated funds for the development of Hemopure for potential use in military and civilian trauma indications and to cover military administrative costs. This funding is being used for trial preparation and for preclinical studies of Hemopure in animal models, including those that mimic military trauma scenarios.

As previously reported, in June 2008 the NMRC submitted and subsequently withdrew an Op RESUS protocol for a Phase 2 clinical trial of Hemopure for resuscitation of operations casualties with severe traumatic hemor
'/>"/>

SOURCE Biopure Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Globus Medical Raises $110 Million in Series E Financing Round
6. Quark Pharmaceuticals Appoints New Chief Medical Officer
7. Boston University Biomedical Engineers Find Chink in Bacterias Armor
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
11. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... -- Boston Biomedical, an industry leader in the development of ... pathways, will present clinical data today on the investigational ... the 2015 American Society of Clinical Oncology (ASCO) annual ... Data presented at ASCO highlight the potential of BBI608 ... to inhibition of the critical genes for maintaining cancer ...
(Date:6/1/2015)... /CNW Telbec/ -  Ergoresearch Ltd (TSXV: ERG) – based ... « Équilibre, orthèses et biomécanique» banner  – announces its ... All dollar amounts in the present release are in Canadian ... fiscal year 2015 ended this past March 31, 2015 totaled ... for the quarter ended March 31, 2014. This decrease can ...
(Date:6/1/2015)... 1, 2015 /PRNewswire/ - Merus Labs International Inc. ("Merus" ... ) is pleased to announce today that the ... the over-allotment option to purchase 1,000,550 common shares ... C$3.05 per Share granted to the Underwriters in ... which closed on April 30, 2015.  The Company ...
Breaking Medicine Technology:Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 2Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 3Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 4Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 5Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 6Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types 7Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 4Merus Labs International Inc. Announces Closing of Exercise of Over-Allotment Option 2
... 2011 S*BIO Pte Ltd today announced that its ... (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive ... in vitro data on SB2343 were presented ... on Targeting PI3K/mTOR Signaling in Cancer held in San ...
... Feb. 28, 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: ... Appeal of the European Patent Office (EPO) has cancelled its ... decision upholding PDL,s  European Patent No. 0 451 216B (the ... the termination of the opposition appeal proceeding is that the ...
Cached Medicine Technology:S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 2S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 3PDL BioPharma Announces European Patent Office Determination of Validity of PDL's European Patent is Final 2
(Date:6/1/2015)... June 01, 2015 On May 14, ... center hosted the Cherry Creek Chamber of Commerce ... clinic. Urgent care centers typically do not offer primary ... AFC/Doctors Express Cherry Creek Urgent Care staff to schedule ... , From 5:30 to 7:30 p.m. the center hosted ...
(Date:6/1/2015)... "This milestone opens the doors to institutional ... to buy and sell shares of our Company. ... make recommendations to clients as they so choose. It ... shares of our Company,” said Kris Finstad, Content Checked’s ... OTCQB provides our investors greater confidence in the information ...
(Date:6/1/2015)... York, NY (PRWEB) June 01, 2015 ... by patients requesting celebrity features. Much like one would ... favorite stars’ noses, eyes, cheeks, chin and more to ... photo filtering apps like FaceTune are ushering in a ... Top Manhattan facial plastic surgeon, Sam Rizk, MD, FACS ...
(Date:6/1/2015)... June 1, 2015 – Atlanta, GA ... the areas of hospital medicine, emergency medicine, and pediatric ... expanded upon its partnership with AgileMD to provide the ... in a mobile application format available on iPhones, ... are very excited about the June 1 launch of ...
(Date:6/1/2015)... InstantLabs will co-develop and commercialize a ... a Cooperative Research and Development Agreement (CRADA) with the ... with U.S. Farm Bill legislation, only members of the ... the United States. , InstantLabs’ DNA-based technology will ... need rather than requiring samples be sent to centralized ...
Breaking Medicine News(10 mins):Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 2Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 3Health News:Content Checked Holdings Inc. Upgrades to the OTCQB Marketplace, now available for trading as CNCK 4Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 2Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 3Health News:InstantLabs Partners with FDA to Commercialize Catfish Species Identification Test 4
... Human papillomavirus infection linked to better prognosis, research suggests ... the human papillomavirus (HPV) may improve survival in patients ... They said the finding may explain why black Americans, ... poorer head and neck cancer survival rates. , "There ...
... , , Association,s Anti-Fraud ... Fraud, and Abuse in Medicare , , ... strongly supports the recent Medicare Fraud Strike Force crackdown on Medicare ... takes vital resources away from seniors and patients. Reducing fraud and ...
... , YOUNTVILLE, Calif., July 30 The following is being ... WHAT: A special hearing of the California Senate Veterans Affairs Committee at the ... was originally , scheduled for Friday, July 31, 2009 at 9 a.m.. , ... , ...
... , , DETROIT, July 30 ... Rev. Dr. Wendell Anthony: , , Congressman Thaddeus ... to apologize for his remarks to the Cambridge Police Department. ... he should start by issuing an apology to the citizens of ...
... PASADENA, Calif., July 30 AutoImmune Inc. (OTC ... Corp., and Eli Lilly and Company reported that dirucotide ... progression, as measured by the Expanded Disability Status Scale ... with secondary progressive multiple sclerosis (SPMS). In addition, there ...
... PLEASANTON, Calif., July 30 Thoratec Corporation (Nasdaq: THOR ... save, support and restore failing hearts, today announced that it will ... months of fiscal 2009 on Wednesday, August 5. , , ... its financial results and operating activities open to all interested parties ...
Cached Medicine News:Health News:Virus May Affect Survival in Head and Neck Cancer 2Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 2Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 3Health News:American Association for Homecare Supports Crackdown on Medicare Scammers in Houston, Boston, New York, Louisiana 4Health News:Clinical Trial by Licensee Does Not Meet Primary Endpoint 2Health News:Thoratec Schedules Second Quarter Conference Call, Webcast 2
Inquire...
... System consists of a sterile Hemostatic ... Compression System.,Both devices work together to ... achieves topical hemostasis by facilitating clotting ... Femoral Compression System provides external compression ...
... PRAXIS is an Electronic Medical Record system. ... EKG's, Vital Statistics, Medications, and everything you would ... charts cost you money. Someone has to write ... them, and organize them. Paper Charts get lost. ...
... Bausch & Lomb's Orbscan IIz is ... elevates diagnostics beyond mere topography. Unlike current ... the eye at standard points, the Orbscan ... 1.5 seconds to meticulously map the entire ...
Medicine Products: